Kura Oncology, founded in 2014, progressed from R&D focus to a commercial-stage biopharma by late 2025 with FDA approval and U.S. launch of KOMZIFTI (ziftomenib), its menin inhibitor targeting relapsed/refractory AML patients with NPM1 mutations. The drug’s differentiated safety profile and market access underpin the company’s moat, supported by collaboration with Kyowa Kirin. Despite initial commercial revenues, Kura continues to report deep losses driven by significant commercialization and research investments, reflected in its worsening operating income and cash flow metrics for fiscal 2025. Its diversified pipeline beyond AML, including next-generation inhibitors targeting solid tumors and diabetes, provides future growth avenues yet uncertain due to clinical and regulatory risks.